Anti-GD2 monoclonal antibody 3F8

DB15388InvestigationalProtein Based Therapies

Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).

Mechanism: Pharmacologically active on Low affinity immunoglobulin gamma Fc region receptor III-A and GD2 disialoganglioside
Curator reviewed
Also known as: 3F8 · ANTI-GD2 MOUSE MONOCLONAL ANTIBODY 3F8 (IGG3) · MONOCLONAL ANTIBODY 3F8

Resolves to

Compound

UNII3GFS72WN4M

Targets

P08637FCGR3AP13591NCAM1

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anti-GD2 monoclonal antibody 3F8, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account